{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T22:48:09Z","timestamp":1784933289677,"version":"3.55.0"},"reference-count":82,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Steroids"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.steroids.2014.06.001","type":"journal-article","created":{"date-parts":[[2014,6,6]],"date-time":"2014-06-06T23:15:52Z","timestamp":1402096552000},"page":"53-59","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Menopausal hormone therapy and cancer: Changing clinical observations of target site specificity"],"prefix":"10.1016","volume":"90","author":[{"given":"Rowan T.","family":"Chlebowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garnet L.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.steroids.2014.06.001_b0005","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/nrc3622","article-title":"Links between oestrogen receptor activation and proteolysis: relevance to hormone-regulated cancer therapy","volume":"14","author":"Zhou","year":"2014","journal-title":"Nat Rev Cancer"},{"issue":"21","key":"10.1016\/j.steroids.2014.06.001_b0010","doi-asserted-by":"crossref","first-page":"8572","DOI":"10.1158\/1078-0432.CCR-13-0325","article-title":"Molecular pathways: estrogen pathway in colorectal cancer","volume":"19","author":"Barzi","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.steroids.2014.06.001_b0015","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1053\/j.seminoncol.2013.12.009","article-title":"Estrongenic steroid hormones in lung cancer","volume":"41","author":"Siegfried","year":"2014","journal-title":"Semin Oncol"},{"key":"10.1016\/j.steroids.2014.06.001_b0020","doi-asserted-by":"crossref","first-page":"479541","DOI":"10.1155\/2013\/479541","article-title":"The estrogen receptor joins other cancer biomarkers as a predictor of outcome","volume":"2013","author":"Leslie","year":"2013","journal-title":"Obstet Gynecol Int"},{"key":"10.1016\/j.steroids.2014.06.001_b0025","doi-asserted-by":"crossref","first-page":"64S","DOI":"10.1016\/j.amjmed.2005.09.059","article-title":"Estrogens and progestins: background and history, trends in use, and guidelines and regimens approved by the US Food and Drug Administration","volume":"188","author":"Stefanick","year":"2005","journal-title":"Am J Med"},{"key":"10.1016\/j.steroids.2014.06.001_b0030","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1056\/NEJM197512042932302","article-title":"Association of exogenous estrogen and endometrial carcinoma","volume":"293","author":"Smith","year":"1975","journal-title":"N Engl J Med"},{"key":"10.1016\/j.steroids.2014.06.001_b0035","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1056\/NEJM197512042932303","article-title":"Increased risk of endometrial carcinoma among users of conjugated estrogens","volume":"293","author":"Ziel","year":"1975","journal-title":"N Engl J Med"},{"key":"10.1016\/j.steroids.2014.06.001_b0040","article-title":"Menopausal hormone therapy and risk of endometrial cancer","author":"Briton","year":"2013","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.steroids.2014.06.001_b0045","first-page":"419","article-title":"Breast cancer and hormone replacement therapy in the Million Women Study","volume":"362","author":"Beral","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.steroids.2014.06.001_b0050","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S0140-6736(97)08233-0","article-title":"Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer","volume":"350","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.steroids.2014.06.001_b0055","doi-asserted-by":"crossref","first-page":"909s","DOI":"10.1158\/1078-0432.909s.11.2","article-title":"Estrogen, estrogen plus progestin therapy, and risk of breast cancer","volume":"11","author":"Colditz","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.steroids.2014.06.001_b0060","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1001\/archinte.166.9.1027","article-title":"Unopposed estrogen therapy and the risk of invasive breast cancer","volume":"166","author":"Chen","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.steroids.2014.06.001_b0065","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1200\/JCO.1998.16.9.3115","article-title":"Low biologic aggressiveness in breast cancer in women using hormone replacement therapy","volume":"16","author":"Holli","year":"1998","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.steroids.2014.06.001_b0070","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.beem.2008.08.001","article-title":"Exogenous and endogenous hormones and breast cancer","volume":"22","author":"Chen","year":"2008","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.steroids.2014.06.001_b0075","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1586\/eem.11.31","article-title":"An epidemiological overview of the relationship between hormone replacement therapy and breast cancer","volume":"6","author":"Salagame","year":"2011","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.steroids.2014.06.001_b0080","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1001\/jama.288.7.872","article-title":"Postmenopausal hormone replacement therapy: scientific review","volume":"288","author":"Nelson","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.steroids.2014.06.001_b0085","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1532-5415.1993.tb06953.x","article-title":"The menopause: health implications and clinical management","volume":"41","author":"Greendale","year":"1993","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.steroids.2014.06.001_b0090","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJM199109123251102","article-title":"Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the Nurse\u2019s Health Study","volume":"325","author":"Stampfer","year":"1991","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.steroids.2014.06.001_b0095","first-page":"277","article-title":"Estrogen replacement therapy I: a 10-year prospective study in the relationship of osteoporosis","volume":"53","author":"Nachtigall","year":"1979","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.steroids.2014.06.001_b0100","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0889-8529(05)70250-4","article-title":"Hormone replacement therapy and other potential treatments for dementias","volume":"26","author":"McBee","year":"1997","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.steroids.2014.06.001_b0105","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1001\/jama.291.1.47","article-title":"National use of menopausal hormone therapy: annual trends and response to recent evidence","volume":"291","author":"Hersh","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.steroids.2014.06.001_b0110","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women\u2019s Health Initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.steroids.2014.06.001_b0115","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1001\/jama.291.14.1701","article-title":"Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women\u2019s Health Initiative randomized controlled trial","volume":"291","author":"Anderson","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.steroids.2014.06.001_b0120","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/S1047-2797(03)00043-7","article-title":"Implementation of the Women\u2019s Health Initiative study design","volume":"13","author":"Anderson","year":"2003","journal-title":"Ann Epidemiol"},{"key":"10.1016\/j.steroids.2014.06.001_b0125","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1001\/jama.289.24.3243","article-title":"Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women\u2019s Health Initiative randomized trial","volume":"289","author":"Chlebowski","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.steroids.2014.06.001_b0130","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/jama.2010.1500","article-title":"Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women","volume":"304","author":"Chlebowski","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.steroids.2014.06.001_b0135","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1001\/archinternmed.2007.123","article-title":"Estrogen plus progestin and breast cancer detection by means of mammography and breast biopsy","volume":"168","author":"Chlebowski","year":"2008","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.steroids.2014.06.001_b0140","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/00001648-200107000-00013","article-title":"Postmenopausal hormone use, screening, and breast cancer: characterization and control of a bias","volume":"12","author":"Joffe","year":"2001","journal-title":"Epidemiology"},{"key":"10.1016\/j.steroids.2014.06.001_b0145","first-page":"2935","article-title":"Incidence of breast cancer before and after implementation of mammography screening","volume":"126","author":"Hofvind","year":"2006","journal-title":"Tidsskr Nor Laegeforen"},{"key":"10.1016\/j.steroids.2014.06.001_b0150","doi-asserted-by":"crossref","first-page":"4103","DOI":"10.1158\/1078-0432.CCR-07-5003","article-title":"Molecular subtypes of breast cancers detected in mammography screening and outside of screening","volume":"14","author":"Sihto","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.steroids.2014.06.001_b0155","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1093\/aje\/kwn044","article-title":"Estrogen plus progestin therapy and breast cancer in recently postmenopausal women","volume":"167","author":"Prentice","year":"2008","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.steroids.2014.06.001_b0160","doi-asserted-by":"crossref","first-page":"5138","DOI":"10.1200\/JCO.2008.21.6432","article-title":"Estrogen-progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks?","volume":"27","author":"Fournier","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.steroids.2014.06.001_b0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jnci\/djq527","article-title":"Breast cancer risk in relation to the interval between menopause and starting hormone therapy","volume":"103","author":"Beral","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.steroids.2014.06.001_b0170","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1093\/jnci\/djq561","article-title":"The influence of time from menopause and mammography on hormone therapy-related breast cancer risk assessment","volume":"103","author":"Chlebowski","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.steroids.2014.06.001_b0175","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1001\/jama.295.14.1647","article-title":"Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy","volume":"295","author":"Stefanick","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.steroids.2014.06.001_b0180","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1001\/jama.2011.382","article-title":"Health risks and benefits 5years after stopping randomized treatment with conjugated equine estrogens in postmenopausal women with prior hysterectomy","volume":"305","author":"Lacroix","year":"2011","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.steroids.2014.06.001_b0185","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S1470-2045(12)70075-X","article-title":"Oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy extended follow-up of the Women\u2019s Health Initiative randomized trial","volume":"13","author":"Anderson","year":"2012","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.steroids.2014.06.001_b0190","first-page":"1","article-title":"The Women\u2019s Health Initiative hormone therapy trials: update and overview of health outcomes during the intervention and post-stopping phases","volume":"310","author":"Manson","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.steroids.2014.06.001_b0195","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1093\/aje\/kwn090","article-title":"Conjugated equine estrogens and breast cancer risk in the Women\u2019s Health Initiative clinical trial and observational study","volume":"167","author":"Prentice","year":"2008","journal-title":"Am J Epidemiol"},{"issue":"4","key":"10.1016\/j.steroids.2014.06.001_b0200","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/GME.0b013e31828865a5","article-title":"The scientific rationale for a delay after menopause in the use of conjugated equine estrogens in postmenopausal women that causes a reduction in breast cancer incidence and mortality","volume":"20","author":"Obiorah","year":"2013","journal-title":"Menopause"},{"issue":"5","key":"10.1016\/j.steroids.2014.06.001_b0205","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S1470-2045(12)70110-9","article-title":"Oestrogen and breast cancer: results from the WHI trial","volume":"13","author":"Howell","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.steroids.2014.06.001_b0210","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","article-title":"Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast Cancer and Bowel Project P-1 Study","volume":"90","author":"Fisher","year":"1998","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"10.1016\/j.steroids.2014.06.001_b0215","doi-asserted-by":"crossref","first-page":"e78016","DOI":"10.1371\/journal.pone.0078016","article-title":"Risk of breast cancer by type of menopausal hormone therapy: a case-control study among post-menopausal women in France","volume":"8","author":"Cordina-Duverger","year":"2013","journal-title":"PLos ONE"},{"key":"10.1016\/j.steroids.2014.06.001_b0220","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/ijc.25314","article-title":"Menopausal hormone therapy and breast cancer risk: impact of different treatments. The European Prospective Investigation into Cancer and Nutrition","volume":"128","author":"Bakken","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.steroids.2014.06.001_b0225","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S0039-128X(03)00138-7","article-title":"Risk of breast cancer with progestins: critical assessment of current data","volume":"68","author":"Santen","year":"2003","journal-title":"Steroids"},{"key":"10.1016\/j.steroids.2014.06.001_b0230","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s10549-007-9523-x","article-title":"Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N-EPIC cohort study","volume":"107","author":"Fournier","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.steroids.2014.06.001_b0235","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1093\/aje\/kwq300","article-title":"Menopausal hormone therapy and risk of endometrial carcinoma among postmenopausal women. European Prospective Investigation into Cancer and Nutrition","volume":"172","author":"Allen","year":"2010","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.steroids.2014.06.001_b0240","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1093\/jnci\/dji279","article-title":"Estrogen plus progestin use and mammographic density in postmenopausal women: Women\u2019s Health Initiative randomized trial","volume":"97","author":"McTiernan","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.steroids.2014.06.001_b0245","doi-asserted-by":"crossref","first-page":"6135","DOI":"10.1200\/JCO.2008.21.7166","article-title":"Conjugated equine estrogen influence on mammographic density in postmenopausal women in a sub-study of the Women\u2019s Health Initiative randomized trial","volume":"27","author":"McTiernan","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.steroids.2014.06.001_b0250","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2009.24.8799","article-title":"Estrogen alone in postmenopausal women and breast cancer detection by means by mammography and breast biopsy","volume":"28","author":"Chlebowski","year":"2010","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.steroids.2014.06.001_b0255","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1093\/jnci\/djn075","article-title":"Conjugated equine estrogen and risk of benign proliferative breast disease: a randomized controlled trial","volume":"100","author":"Rohan","year":"2008","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"10.1016\/j.steroids.2014.06.001_b0260","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1158\/1055-9965.EPI-08-0380","article-title":"Estrogen plus progestin and risk of benign proliferative breast disease","volume":"17","author":"Rohan","year":"2008","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"25","key":"10.1016\/j.steroids.2014.06.001_b0265","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1056\/NEJMoa1103507","article-title":"Exemestane for breast-cancer prevention in postmenopausal women","volume":"364","author":"Goss","year":"2011","journal-title":"N Engl J Med"},{"issue":"9922","key":"10.1016\/j.steroids.2014.06.001_b0270","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(13)62292-8","article-title":"Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial","volume":"383","author":"Cuzick","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.steroids.2014.06.001_b0275","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1158\/1940-6207.CAPR-11-0185","article-title":"Paradoxical clinical effects of estrogen on breast cancer risk: a \u201cnew\u201d biology of estrogen-induced apoptosis","volume":"4","author":"Jordan","year":"2011","journal-title":"Cancer Prev Res"},{"issue":"2","key":"10.1016\/j.steroids.2014.06.001_b0280","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.mce.2010.12.034","article-title":"New and translational perspective of oestrogen deprivation in breast cancer","volume":"340","author":"Dunbier","year":"2011","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.steroids.2014.06.001_b0285","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jsbmb.2005.04.025","article-title":"Adaptive hypersensitivity to estrogen: mechanisms and clinical relevance to aromatase inhibitor therapy in breast cancer treatment","volume":"95","author":"Santen","year":"2005","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.steroids.2014.06.001_b0290","doi-asserted-by":"crossref","first-page":"R30","DOI":"10.1186\/bcr3632","article-title":"Sex hormone associations with breast cancer risk and the mediation of randomized trial postmenopausal hormone therapy effects","volume":"16","author":"Zhao","year":"2014","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.steroids.2014.06.001_b0295","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1001\/jama.299.9.1036","article-title":"Health risks and benefits 3years after stopping randomized treatment with estrogen and progestin","volume":"299","author":"Heiss","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.steroids.2014.06.001_b0300","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/S0140-6736(09)61526-9","article-title":"Estrogen plus progestin and lung cancer in postmenopausal women (Women\u2019s Health Initiative trial): a post-hoc analysis of a randomized controlled trial","volume":"374","author":"Chlebowski","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.steroids.2014.06.001_b0305","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1093\/jnci\/djq285","article-title":"Lung cancer among postmenopausal women treated with estrogen alone in the Women\u2019s Health Initiative randomized trial","volume":"102","author":"Chlebowski","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.steroids.2014.06.001_b0310","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1002\/(SICI)1097-0142(19961115)78:10<2119::AID-CNCR12>3.0.CO;2-1","article-title":"Gender influence on weight-loss pattern and survival of non-small cell lung carcinoma patients","volume":"78","author":"Palomares","year":"1996","journal-title":"Cancer"},{"key":"10.1016\/j.steroids.2014.06.001_b0315","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1053\/j.seminoncol.2009.10.007","article-title":"Gender-associated differences in lung cancer: clinical characteristics and treatment outcomes in women","volume":"36","author":"Harichand-Herdt","year":"2009","journal-title":"Semin Oncol"},{"key":"10.1016\/j.steroids.2014.06.001_b0320","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1093\/carcin\/bgq156","article-title":"Serum estrogen and tumor-positive estrogen receptor-alpha are strong prognostic classifers of non-small-cell lung cancer survival in both men and women","volume":"31","author":"Olivo-Marston","year":"2010","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.steroids.2014.06.001_b0325","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1749-6632.2009.04116.x","article-title":"Targeting aromatase and estrogen signaling in human non-small cell lung cancer","volume":"115","author":"Marquez-Garban","year":"2009","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/j.steroids.2014.06.001_b0330","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/S0002-9343(99)00063-7","article-title":"Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis","volume":"106","author":"Grodstein","year":"1999","journal-title":"Am J Med"},{"issue":"32","key":"10.1016\/j.steroids.2014.06.001_b0335","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1200\/JCO.2012.42.7732","article-title":"Estrogen plus progestin and colorectal cancer incidence and mortality","volume":"30","author":"Simon","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.steroids.2014.06.001_b0340","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1056\/NEJMoa032071","article-title":"Estrogen plus progestin and colorectal cancer in postmenopausal women","volume":"350","author":"Chlebowski","year":"2004","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.steroids.2014.06.001_b0345","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3322\/caac.21220","article-title":"Colorectal cancer statistics, 2014","volume":"64","author":"Siegel","year":"2014","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.steroids.2014.06.001_b0350","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1158\/1055-9965.EPI-08-0385","article-title":"Conjugated equine estrogens and colorectal cancer incidence and survival: the Women\u2019s Health Initiative randomized clinical trial","volume":"17","author":"Ritenbaugh","year":"2008","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.steroids.2014.06.001_b0355","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/S0140-6736(05)66455-0","article-title":"Endometrial cancer and hormone-replacement therapy in the Million Women Study","volume":"365","author":"Beral","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.steroids.2014.06.001_b0360","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/ijc.24672","article-title":"Reproductive factors and postmenopausal hormone use in relation to endometrial cancer risk in the Nurses\u2019 Health Study cohort 1976\u20132004","volume":"126","author":"Karageorgi","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1016\/j.steroids.2014.06.001_b0365","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1001\/jama.290.13.1739","article-title":"Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures. The Women\u2019s Health Initiative randomized trial","volume":"290","author":"Anderson","year":"2003","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.steroids.2014.06.001_b0370","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.ygyno.2007.12.003","article-title":"Hormone replacement therapy and ovarian cancer risk: a meta-analysis","volume":"108","author":"Zbuk","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.steroids.2014.06.001_b0375","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/gme.0b013e3181f43404","article-title":"Trends in menopausal hormone therapy use of US office-based physicians, 2000\u20132009","volume":"18","author":"Tsai","year":"2011","journal-title":"Menopause"},{"issue":"33","key":"10.1016\/j.steroids.2014.06.001_b0380","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1200\/JCO.2006.08.6504","article-title":"Recent declines in hormone therapy utilization and breast cancer incidence. clinical and population-based evidence","volume":"24","author":"Clarke","year":"2006","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.steroids.2014.06.001_b0385","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1056\/NEJMsr070105","article-title":"The decrease in breast cancer incidence in 2003 in the United States","volume":"356","author":"Ravdin","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.steroids.2014.06.001_b0390","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1056\/NEJMoa0807684","article-title":"Breast cancer after estrogen plus progestin use in postmenopausal women","volume":"360","author":"Chlebowski","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.steroids.2014.06.001_b0395","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/jech.2008.083774","article-title":"Declining incidence of breast cancer after decreased use of hormone-replacement therapy: magnitude and time lags in different countries","volume":"66","author":"Zbuk","year":"2012","journal-title":"J Epidemiol Community Health"},{"issue":"4","key":"10.1016\/j.steroids.2014.06.001_b0400","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.canep.2013.03.008","article-title":"Recent changes in endometrial cancer trends among menopausal-age US women","volume":"37","author":"Wartko","year":"2013","journal-title":"Cancer Epidemiol"},{"issue":"4","key":"10.1016\/j.steroids.2014.06.001_b0405","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.maturitas.2012.01.002","article-title":"Stopping menopausal hormone therapy: If breast cancer really decreased, why did colorectal cancer not increase?","volume":"71","author":"Nahum","year":"2012","journal-title":"Maturitas"},{"issue":"13","key":"10.1016\/j.steroids.2014.06.001_b0410","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1001\/jama.2013.278042","article-title":"The Women\u2019s Health Initiative \u2013 a victory for women and their health","volume":"310","author":"Nabel","year":"2013","journal-title":"JAMA"}],"container-title":["Steroids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039128X14001251?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039128X14001251?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T01:22:10Z","timestamp":1689297730000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039128X14001251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":82,"alternative-id":["S0039128X14001251"],"URL":"https:\/\/doi.org\/10.1016\/j.steroids.2014.06.001","relation":{},"ISSN":["0039-128X"],"issn-type":[{"value":"0039-128X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Menopausal hormone therapy and cancer: Changing clinical observations of target site specificity","name":"articletitle","label":"Article Title"},{"value":"Steroids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.steroids.2014.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}